Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Affiliations

• ¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ² Weill Cornell Medical College, New York, NY, USA.
• ³ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
• ⁴ University Medicine Essen, Ruhrlandklinik, Department of Interventional Pulmonology, University Duisburg-Essen, Essen, Germany.
• ⁵ German Cancer Research Center (DKFZ), A420, Heidelberg, Germany.
• ⁶ Fifth Medical Department, Section of Pulmonology, Faculty of the University of Heidelberg, University Medicine Mannheim, Mannheim, Germany.
• ⁷ University of Colorado School of Medicine, Aurora, CO, USA.
• ⁸ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹⁰ Brigham and Women's Hospital, Boston, MA, USA.
• ¹¹ The Ohio State University Wexner Medical Center, Columbus, OH, USA.
• ¹² David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ¹³ Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland.
• ¹⁴ Centre for Data Analysis, Modeling and Computational Sciences, University of Lodz, Lodz, Poland.
• ¹⁵ Genentech, Inc., South San Francisco, CA, USA.
• ¹⁶ Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
• ¹⁷ Washington University School of Medicine, St. Louis, MO, USA.
• ¹⁸ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. david.carbone@osumc.edu.
• ¹⁹ Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA. david.carbone@osumc.edu.